We offer diagnosis and monitoring of patients with EGFR mutated lung cancer by measuring EGFR mutated circulating tumor DNA in a plasma sample.

Plasma DNA samples can be taken at diagnosis and during therapy. The presence of 41 EGFR mutations is determined. This includes activating EGFR mutations as well as the T790M mutation mediating resistance to EGFR directed therapy. Presence of T790M in plasma samples at progression on first line tyrosine kinase inhibitor suggests new treatment for example Tagrisso.

Presence of EGFR mutations in plasma DNA can also be used as a marker of residual disease.

All steps of the analysis are performed with state-of-the-art technologies. 

We offer interpretation service and counselling in relation to the results obtained from these tests. 

Research and development projects include:

• Diagnosis and monitoring of ALK translocated lung cancers using circulating tumor DNA.
• Diagnosis of the presence of cancer with a larger gene panel covering 22 frequent lung cancer oncogenes.

Further information:
Please contact consultant, MD, PhD Søren Ladefoged: soerelade@rm.dk Tel +45 4046 5965.